Catalent announced today that it completed the expansion of two new suites at its biologics manufacturing facility in Madison, Wis. Somserset, N.J.-based Catalent also commenced work on customer programs in addition to completing the expansion of the biologics drug substance development and manufacturing facility, according to a news release. The company now has five manufacturing…
Catalent to produce J&J’s COVID-19 vaccine in Indiana
Catalent will produce millions of extra doses of Johnson & Johnson’s COVID-19 vaccine at its recently expanded Bloomington, Ind. facility, according to a statement posted on LinkedIn. Bloomberg broke the news yesterday, reporting that FDA has authorized the use of the facility to make the J&J vaccine. Catalent announced late last year that it would…
Catalent to acquire Acorda’s manufacturing and packaging operations
Catalent (NYSE:CTLT) has entered into a definitive agreement to purchase a dry-powder inhaler (DPI) capsule manufacturing and packaging facility from Acorda Therapeutics (NSDQ:ACOR). The acquisition will enable Catalent to establish a center of excellence for spray-dried dispersion for DPI capsule manufacturing. The transaction will also expand Catalent’s existing U.S.-based commercial-scale capabilities in metered-dose inhalers and nasal…
Moderna, Catalent partner on COVID-19 vaccine candidate manufacturing
Moderna (NSDQ:MRNA) and Catalent (NYSE:CTLT) today announced a collaboration for large-scale, commercial fill-finish manufacturing of Moderna’s mRNA-based COVID-19 vaccine candidate (mRNA-1273) at Catalent’s biologics facility in Bloomington, Ind. Catalent will provide vial filling and packaging capacity, as well as additional staffing required for 24×7 manufacturing operations at the site to support production of an initial 100 million…